BRIM BIOTECHNOLOGY, INC.
Update：2023/06/12
Industries
Main Industry
Biotechnology
Main Product/Service
1. BRM421 for Dry Eye Disease
2. BRM423 for Corneal Damage Repair
3. BRM424 for Neurotrophic Keratitis
4. BRM521 for Treatment of Osteoarthritis
2. BRM423 for Corneal Damage Repair
3. BRM424 for Neurotrophic Keratitis
4. BRM521 for Treatment of Osteoarthritis
Founded Year
2013
Unified Business No.
54346233
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,323,100,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2022)、Listing(2024)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
BRIM Biotechnology brings together experts across science, engineering, and technology disciplines to deliver a more efficient, less costly, drug development process. Our talented team has forged decades worth of strong global connections and experience. We operate based on a virtual team model, integrating our expert R&D operation team in Taiwan with our skilled overseas scientific team. We have years of experience working in technological and pharmaceutical development, regulatory affairs, and marketing and IP, with expertise across the field of innovative drug development, including pre-clinical toxicology, clinical pharmacology, and management. We harness the power of our team’s expertise in translational science to deliver a difference for patients.
